Roivant Sciences Ltd Ordinary Shares ROIV 深 滬
等待開盤 09-04 09:30:00 美东时间
12.59
+0.200
+1.61%
華盛通- 最 高12.745
- 今 開12.38
- 成交量 1039.23万股
- 最 低 12.28
- 昨 收 12.39
- 總市值 85.99亿
- 52周最高 12.935
- 市盈率 靜 --
- 換手率 1.52%
- 52周最低 8.73
- 委 比 2.53%
- 總股本 6.83亿
- 歷史最高 16.76
- 量 比 1.88
- 振 幅 3.75%
- 歷史最低 2.52
- 每 手 1
- 風險率 0.89%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Roivant Sciences Announces Promising Study Results
Roivant Sciences ( ($ROIV) ) has provided an update. On September 3, 2025, Roiv...
今天 01:57
Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
<p>Immunovant's batoclimab shows promising results for uncontrolled Graves' disease patients, with 80% achieving normal thyroid function after six months off treatment. Of these, 50% achieved anti-thyroid drug-free remission. Two registrational trials for IMVT-1402 are ongoing, with results expected in 2027. Immunovant will discuss these updates during an investor call on September 3, 2025.</p>
09-03 17:01
Citigroup Initiates Coverage On Roivant Sciences with Buy Rating, Announces Price Target of $16
Citigroup analyst Samantha Semenkow initiates coverage on Roivant Sciences (NASDAQ:ROIV) with a Buy rating and announces Price Target of $16.
09-02 20:02
Roivant Sciences Q1 2026 Adj. EPS $(0.25) Beats $(0.30) Estimate, Sales $2.170M Down From $7.990M YoY
Roivant Sciences (NASDAQ:ROIV) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.30) by 16.67 percent. This is a 47.06 percent decrease over losses of $(0.17) per share from
08-11 19:05
Earnings Scheduled For August 11, 2025
Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to rep...
08-11 16:32
A Glimpse of Roivant Sciences's Earnings Potential
Roivant Sciences (NASDAQ:ROIV) is preparing to release its quarterly earnings o...
08-08 22:05
470亿港元合作：晶泰控股与哈佛教授Verdine创AI制药史上合作订单新纪录
2025年8月5日，晶泰控股（02228.HK）宣布与哈佛大学教授Gregory Verdine创立的DoveTree正式签署最终协议，合作总规模达470亿港元...
08-07 11:50
Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025
Roivant announced it will host a live conference call and webcast on August 11, 2025, at 8:00 a.m. ET, to discuss its Q1 2025 financial results and provide a business update. Registration for the call is available via a provided link, and webcast details will be accessible on its投资者 section. Roivant, a biopharmaceutical company, focuses on accelerating medicine development and commercialization, with a pipeline including IMVT-1402, batoclimab, br...
07-28 20:05
Roivant Sciences sets $500M stock repurchase program
Roivant Sciences (NASDAQ:ROIV) has set a stock repurchase program to buy back up to $500M of its common shares. The program will be funded with available cash and cash equivalents on hand and does not...
06-25 19:51
Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis
Roivant and Priovant Therapeutics are hosting a live investor video conference on June 17, 2025, to discuss brepocitinib, a potential treatment for dermatomyositis (DM). Brepocitinib is a dual inhibitor of TYK2 and JAK1, targeting cytokines linked to autoimmunity. It is in Phase 3 trials for DM and non-infectious uveitis, and Phase 2 for cutaneous sarcoidosis. Roivant, a biopharmaceutical company, also develops other therapies like mosliciguat fo...
06-09 20:05
